Program
HRS-5041
A development code. Also written as “HRS-5041 Single dose of HRS-5041 orally administered”, “HRS-5041 tablets” and “HRS-5041 Tablets”.
In Jiangsu HengRui Medicine's pipeline, AR PROTAC
. Its studies are mostly in Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 53 open or running | phase 2since Aug 21, 2024 | Jul 5, 2023 | Dec 2026phase 2 · NCT06568094 |
| Hansoh Pharmaceutical Group | 11 open or running | phase 1since Aug 4, 2025 | Aug 4, 2025 | Dec 2027phase 1 · NCT07115446 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-5041
, phase 2, as of Jul 31, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 5, 2023First study: phase 1 study in Advanced Prostate CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05942001 · 100 planned · China
- Aug 2, 2024Phase 1 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06559007 · 24 enrolled · Australia
- Aug 21, 2024Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094 · 100 planned · China
- Feb 12, 2025Phase 1 study in Metastatic Castration Resistant Prostate CancerJiangsu HengRui Medicine · NCT06830850 · 25 enrolled · Australia
- Jun 3, 2025Phase 1 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT07014488 · 16 enrolled · China
- Aug 4, 2025Hansoh Pharmaceutical Group's first study: phase 1 study in Advanced Prostate CancerNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT07115446 · 63 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094
- Dec 30, 2026Primary completion: phase 1 study in Metastatic Castration Resistant Prostate CancerJiangsu HengRui Medicine · NCT06830850
- Dec 2027Primary completion: phase 1 study in Advanced Prostate CancerHansoh Pharmaceutical Group · NCT07115446
TargetBeta
“AR PROTAC”the company's pipeline, read by Claude · source
“HRS-5041 is a Proteolysis Targeting Chimeras (PROTAC) targeting androgen receptors.”study summary, read by Claude · the study
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07115446Advanced Prostate Cancer · China | 1 | Recruiting | Hansoh Pharmaceutical Group | Dec 2027 | 63 |
| NCT07014488Prostatic Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 1, 2025 | 16 |
| NCT06830850Metastatic Castration Resistant Prostate Cancer · Australia | 1 | Active, not recruiting | Jiangsu HengRui Medicine | Dec 30, 2026 | 25 |
| NCT06568094Prostatic Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2026 | 100 |
| NCT06559007Prostatic Neoplasms · Australia | 1 | Completed | Jiangsu HengRui Medicine | Jan 6, 2025 | 24 |
| NCT05942001Advanced Prostate Cancer · China | 1 | Recruiting | Jiangsu HengRui Medicine | Sep 2026 | 100 |
How it is read
Names in the registry
- “HRS-5041”, 2 entries
- “HRS-5041 Single dose of HRS-5041 orally administered”, 1 entry
- “HRS-5041 tablets”, 1 entry
- “HRS-5041 Tablets”, 1 entry
- “HRS-5041 dose level 1”, 1 entry
Codes read as this program: HRS5041.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.